[CAS NO. ] SemaglutideTFA

Name: SemaglutideTFA
Brand: Arctom Scientific
SKU: HY-114118A

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS

Store

Catalog

HY-114118A

Brand

MCE

CAS

DESCRIPTION

Overview

MDL	-
Molecular Weight	4227.66
Molecular Formula	C189H292F3N45O61
SMILES	-

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]Int J Mol Med. 2021 Dec;48(6):219.

Summary

Semaglutide TFA, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide TFA has the potential for type 2 diabetes treatment.

IC50 & Target

GLP-1 receptor ^[1] .

In Vitro

Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib ⁸ , Arg ³⁴ ) and is derivatized at lysine 26. The GLP-1R affinity of Semaglutide is 0.38±0.06 nM ^[1] . Semaglutide is a GLP-1 analogue with 94% sequence omology to human GLP-1 ^[3 .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The plasma half-life of Semaglutide is 46h in mini-pigs following i.v. administration and semaglutide has an MRT of 63.6h after s.c. dosing to mini-pigs ^[1] . Semaglutide improves 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced motor impairments. In addition, Semaglutide rescues the decrease of tyrosine hydroxylase (TH) levels, alleviates the inflammation response, reduces lipid peroxidation, inhibits the apoptosis pathway, and also increases autophagy- related protein expression, to protect dopaminergic neurons in the substantia nigra and striatum. Moreover, the long-acting GLP-1 analogue semaglutide is superior to liraglutide in most parameters ^[2] . Semaglutide lowers blood glucose by stimulating the release of insulin and also lowers body weight ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT05429593	Novo Nordisk A+S	Healthy Volunteers	June 22, 2022	Phase 1
NCT03191396	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	June 27, 2017	Phase 3
NCT04019197	Case Western Reserve University\|Medical University of South Carolina\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	HIV+AIDS\|Lipohypertrophy\|Obesity	May 16, 2019	Phase 2
NCT03574597	Novo Nordisk A+S	Overweight\|Obesity	October 24, 2018	Phase 3
NCT01930188	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	December 2, 2013	Phase 3
NCT05443334	Novo Nordisk A+S	Diabetes Mellitus, Type 2	July 28, 2022
NCT02607865	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	February 15, 2016	Phase 3
NCT03919929	University of Colorado, Denver\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	PCOS\|Adolescent Obesity\|NAFLD	May 3, 2019	Phase 2\|Phase 3
NCT01866748	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2\|Healthy	May 2013	Phase 1
NCT04143945	Novo Nordisk A+S	Healthy Volunteers Diabetes Mellitus, Type 2\|Healthy Volunteers Overweight\|Healthy Volunteers Obesity	October 28, 2019	Phase 2
NCT04878393	Novo Nordisk A+S	Diabetes Mellitus, Type 2	April 30, 2021
NCT03631186	Novo Nordisk A+S	Diabetes Mellitus, Type 2	September 12, 2018
NCT04251156	Novo Nordisk A+S	Overweight\|Obesity\|Diabetes Mellitus, Type 2	December 8, 2020	Phase 3
NCT05394519	Novo Nordisk A+S	Overweight\|Obesity\|Type 2 Diabetes Mellitus	February 1, 2023	Phase 3
NCT04263415	University Medical Centre Ljubljana	PCOS\|Semaglutide\|Taste, Altered\|Tongue Tissue Transcriptome\|Gastric Emptying\|Central Neural Response	November 2, 2019	Phase 4
NCT05305794	Centre Hospitalier Universitaire Dijon	Double Diabetes	July 12, 2022	Phase 3
NCT05537233	University of Colorado, Denver\|Juvenile Diabetes Research Foundation	Type 1 Diabetes\|Obesity	January 1, 2023	Phase 2
NCT05478252	Novo Nordisk A+S	Diabetes Mellitus, Type 2	August 3, 2022	Phase 3
NCT04153929	Boehringer Ingelheim	Diabetes Mellitus, Type 2	April 30, 2020	Phase 2
NCT04447859	Tel-Aviv Sourasky Medical Center	Diabetes type2	February 23, 2020	Phase 3
NCT04067999	Novo Nordisk A+S	Diabetes Mellitus, Type 2	August 5, 2019
NCT03707990	Novo Nordisk A+S	Obesity and Overweight	October 15, 2018	Phase 1
NCT05520775	University of North Carolina, Chapel Hill\|National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Alcohol Use Disorder\|Cigarette Smoking	September 2, 2022	Phase 2
NCT04175665	LMC Diabetes & Endocrinology Ltd.	Type 2 Diabetes	January 6, 2020
NCT02773381	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	June 2, 2016	Phase 1
NCT04238962	Novo Nordisk A+S	Overweight\|Obesity	February 3, 2020	Phase 1
NCT05303857	University of Erlangen-Nürnberg Medical School	Diabetes Mellitus, Type 2	March 3, 2022	Phase 4
NCT01686945	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2\|Healthy	September 19, 2012	Phase 1
NCT02249910	Novo Nordisk A+S	Diabetes\|Healthy	September 18, 2014	Phase 1
NCT04287179	Novo Nordisk A+S	Diabetes Mellitus, Type 2	March 9, 2020	Phase 3
NCT05087342	Loma Linda University\|Novo Nordisk A+S	Obesity\|Obesity; Drug\|Overweight or Obesity\|Weight Loss\|Weight Loss Trajectory\|Weight, Body	September 2022	Phase 3
NCT03010475	Novo Nordisk A+S	Diabetes\|Healthy	January 5, 2017	Phase 1
NCT04466345	University Health Network, Toronto	Major Depressive Disorder	October 6, 2021	Phase 2
NCT03724981	Eli Lilly and Company	Diabetes Mellitus, Type 2	October 18, 2018	Phase 4
NCT03987451	Novo Nordisk A+S	Non-alcoholic Steatohepatitis	June 18, 2019	Phase 2
NCT05153564	Novo Nordisk A+S	Diabetes Mellitus, Type 2	December 13, 2021	Phase 1
NCT02845219	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	July 2016	Phase 1
NCT02849080	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	September 20, 2016	Phase 3
NCT05419726	University of California, Los Angeles	Obesity	July 1, 2022
NCT03611582	Novo Nordisk A+S	Overweight\|Obesity	August 1, 2018	Phase 3
NCT03136484	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	March 15, 2017	Phase 3
NCT02054897	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	February 3, 2014	Phase 3
NCT03144271	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2\|Healthy	June 11, 2007	Phase 1
NCT05227196	Novo Nordisk A+S	Healthy Volunteers\|Type 2 Diabetes	February 4, 2022	Phase 1
NCT03842202	Novo Nordisk A+S	Overweight\|Obesity	February 15, 2019	Phase 1
NCT04601753	Novo Nordisk A+S	Diabetes Mellitus, Type 2	November 12, 2020
NCT05435677	Novo Nordisk A+S	Diabetes Mellitus, Type 2	June 22, 2022	Phase 1
NCT05442450	Asian Institute of Gastroenterology, India	Obesity\|Weight Loss	July 10, 2022	Phase 4
NCT05548647	University of Pennsylvania\|Novo Nordisk A+S	Obesity	July 26, 2022	Phase 4
NCT02060266	Novo Nordisk A+S	Diabetes\|Healthy	February 4, 2014	Phase 1
NCT04538352	The Cleveland Clinic\|Novo Nordisk A+S	Type 2 Diabetes	January 18, 2021	Phase 4
NCT01572753	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2\|Healthy	April 12, 2012	Phase 1
NCT05064735	Novo Nordisk A+S	Obesity	October 1, 2021	Phase 3
NCT05530577	University of North Carolina, Chapel Hill\|National Institute on Drug Abuse (NIDA)	Tobacco Use Disorder\|Nicotine Addiction	October 7, 2022	Phase 2
NCT04560998	Novo Nordisk A+S	Diabetes Mellitus, Type 2\|Peripheral Arterial Disease	October 1, 2020	Phase 3
NCT04012255	Novo Nordisk A+S	Overweight\|Obesity	July 15, 2019	Phase 1
NCT02970942	Novo Nordisk A+S	Hepatobiliary Disorders\|Non-alcoholic Steatohepatitis	November 30, 2016	Phase 2
NCT04383197	University of Copenhagen	Type 2 Diabetes	December 10, 2019	Not Applicable
NCT02920385	Novo Nordisk A+S	Diabetes\|Healthy	October 10, 2016	Phase 1
NCT04940078	Novo Nordisk A+S	Obesity & Overweight	July 7, 2021	Phase 1
NCT05441267	University of Oxford\|Novo Nordisk A+S	Diabetes Mellitus, Type 2	December 2022	Phase 4
NCT03086330	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	March 15, 2017	Phase 3
NCT04596631	Novo Nordisk A+S	Diabetes Mellitus, Type 2	November 2, 2020	Phase 3
NCT01885208	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	December 2, 2013	Phase 3
NCT02210871	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2\|Hepatic Impaired	August 7, 2014	Phase 1
NCT03811574	Novo Nordisk A+S	Overweight\|Obesity	January 21, 2019	Phase 3
NCT04817644	Novo Nordisk A+S	Diabetes Mellitus, Type 2	September 10, 2021	Phase 1
NCT03021187	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	February 2, 2017	Phase 3
NCT05316662	Novo Nordisk A+S	Diabetes Mellitus, Type 2	November 6, 2022
NCT03288740	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	September 21, 2017	Phase 1
NCT05040971	Novo Nordisk A+S	Obesity	September 6, 2021	Phase 3
NCT03638778	Novo Nordisk A+S	Diabetes Mellitus, Type 2	August 17, 2018	Phase 1
NCT05202353	Boehringer Ingelheim	Obesity	March 15, 2023	Phase 1
NCT05132088	Novo Nordisk A+S	Overweight and Obesity	November 16, 2021	Phase 3
NCT04865744	University of Tartu	Healthy	May 10, 2021	Phase 4
NCT04624672	Geisinger Clinic\|Novo Nordisk A+S	Diabetes Mellitus, Type 2	August 25, 2021	Phase 4
NCT05473286	Novo Nordisk A+S	Diabetes Mellitus, Type 2	September 30, 2022
NCT01923181	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	December 2, 2013	Phase 2
NCT03466567	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	March 15, 2018	Phase 1
NCT05390307	Dasman Diabetes Institute	Type 1 Diabetes	May 22, 2022	Not Applicable
NCT03819153	Novo Nordisk A+S	Diabetes Mellitus, Type 2	June 17, 2019	Phase 3
NCT04889183	University Medical Center Groningen\|Novo Nordisk A+S	Obesity\|Albuminuria	March 14, 2022	Phase 3
NCT05147896	University Medical Centre Ljubljana\|University of Palermo	Diabetes Mellitus, Type 2\|Atherosclerosis	May 1, 2022	Not Applicable
NCT05514535	Novo Nordisk A+S	Diabetes Mellitus, Type 2\|Obesity	August 29, 2022	Phase 3
NCT05567796	Novo Nordisk A+S	Obesity	November 1, 2022	Phase 3
NCT02249871	Novo Nordisk A+S	Diabetes\|Healthy	September 24, 2014	Phase 1
NCT04451837	Region Skane\|Göteborg University	Type2 Diabetes	September 10, 2020	Phase 2
NCT03548987	Novo Nordisk A+S	Metabolism and Nutrition Disorder\|Obesity	June 4, 2018	Phase 3
NCT04109508	Novo Nordisk A+S	Healthy Volunteers\|Type 2 Diabetes	October 2, 2019	Phase 1
NCT04873245	University of Minnesota	Obesity, Childhood	March 15, 2022	Phase 2
NCT04216589	National Institute of Allergy and Infectious Diseases (NIAID)\|The University of Texas Health Science Center, Houston	HIV Infections\|Non-Alcoholic Fatty Liver Disease	October 1, 2020	Phase 2
NCT02557620	Novo Nordisk A+S	Diabetes\|Healthy	September 2015	Phase 1
NCT04971785	Gilead Sciences\|Novo Nordisk A+S	Nonalcoholic Steatohepatitis	August 9, 2021	Phase 2
NCT04788511	Novo Nordisk A+S	Obesity	March 16, 2021	Phase 3
NCT01272973	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2\|Healthy	January 2011	Phase 1
NCT05302596	State University of New York at Buffalo	Obesity\|Aging	September 1, 2022	Phase 4
NCT04777396	Novo Nordisk A+S	Early Alzheimer´s Disease	May 18, 2021	Phase 3
NCT05424003	Virginia Commonwealth University\|Novo Nordisk A+S	NAFLD	December 2022	Phase 2
NCT04017832	Novo Nordisk A+S	Diabetes Mellitus, Type 2	July 29, 2019	Phase 3
NCT03899402	State University of New York at Buffalo\|University of Glasgow\|Juvenile Diabetes Research Foundation	Type 1 Diabetes Mellitus	May 1, 2019	Phase 2\|Phase 3
NCT04032197	Novo Nordisk A+S	Diabetes Mellitus, Type 2	August 12, 2019	Phase 1
NCT05195944	University Health Network, Toronto\|Novo Nordisk A+S	Liver Transplant; Complications\|Diabetes Mellitus\|NASH - Nonalcoholic Steatohepatitis\|NAFLD	October 26, 2022	Phase 4
NCT05502562	Novo Nordisk A+S	Diabetes Mellitus, Type 2	November 1, 2022
NCT02016911	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2\|Healthy	December 12, 2013	Phase 1
NCT04189848	Novo Nordisk A+S	Healthy Volunteers\|Diabetes Mellitus, Type 2\|Overweight\|Obesity	December 3, 2019	Phase 4
NCT02254291	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	October 2, 2014	Phase 3
NCT02070510	Novo Nordisk A+S	Diabetes\|Healthy	February 27, 2014	Phase 1
NCT04822181	Novo Nordisk A+S	Non-alcoholic Steatohepatitis	April 1, 2021	Phase 3
NCT00833716	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2\|Renal Impairment	February 2, 2009	Phase 1
NCT02022254	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2\|Healthy	December 17, 2013	Phase 1
NCT02648204	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	January 6, 2016	Phase 3
NCT04261933	Novo Nordisk A+S	Diabetes Mellitus, Type 2	February 13, 2020
NCT03018028	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	January 10, 2017	Phase 3
NCT04741074	Geisinger Clinic	CKD\|Diabetic Kidney Disease\|Type 2 Diabetes Mellitus in Obese\|Obesity\|Severe Obesity	July 23, 2021	Phase 3
NCT04601740	Novo Nordisk A+S	Diabetes Mellitus, Type 2	November 17, 2020
NCT03552757	Novo Nordisk A+S	Obesity\|Overweight	June 4, 2018	Phase 3
NCT03693430	Novo Nordisk A+S	Overweight\|Obesity	October 5, 2018	Phase 3
NCT05035095	Novo Nordisk A+S	Obesity\|Overweight	September 13, 2021	Phase 3
NCT03648281	Novo Nordisk A+S	Diabetes Mellitus, Type 2	August 24, 2018
NCT04097600	Novo Nordisk A+S	Healthy Volunteers\|Type 2 Diabetes	September 30, 2019	Phase 1
NCT02161588	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2\|Healthy	June 2014	Phase 1
NCT04938388	Sansum Diabetes Research Institute\|Novo Nordisk A+S	Diabetes Mellitus, Type 2\|Glucose Metabolism Disorders (Including Diabetes Mellitus)	January 29, 2022	Phase 4
NCT03987074	Gilead Sciences\|Novo Nordisk A+S	Nonalcoholic Steatohepatitis	July 29, 2019	Phase 2
NCT02146079	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2\|Healthy	May 21, 2014	Phase 1
NCT04537637	Novo Nordisk A+S	Diabetes Mellitus, Type 2	August 31, 2020
NCT02212067	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	August 11, 2014	Phase 1
NCT05616013	Versanis Bio, Inc.	Obesity\|Obese\|Overweight or Obesity	December 2022	Phase 2
NCT02207374	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	August 4, 2014	Phase 3
NCT04513704	Novo Nordisk A+S	Healthy Volunteers Type 2 Diabetes	August 28, 2020	Phase 1
NCT05468632	Novo Nordisk A+S	Diabetes Mellitus, Type 2	July 5, 2022
NCT05230615	Novo Nordisk A+S	Diabetes Mellitus, Type 2	April 1, 2022
NCT05501483	Karolinska Institutet\|Karolinska University Hospital	Type 2 Diabetes	September 1, 2022	Not Applicable
NCT04537624	Novo Nordisk A+S	Diabetes Mellitus, Type 2	August 24, 2020
NCT05071417	Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León	Atheroscleroses, Coronary	November 2021	Phase 3
NCT02079870	Novo Nordisk A+S	Diabetes\|Metabolism and Nutrition Disorder\|Obesity	March 6, 2014	Phase 1
NCT05371496	Mayo Clinic\|United States Department of Defense	Cardiomyopathy\|Heart Failure With Preserved Ejection Fraction (HFpEF)\|Obesity	September 6, 2022	Phase 2
NCT04469855	Novo Nordisk A+S	Diabetes Mellitus, Type 2	July 27, 2020
NCT04083820	Novo Nordisk A+S	Diabetes Mellitus, Type 2	September 16, 2019
NCT02231684	Novo Nordisk A+S	Diabetes\|Healthy	September 2014	Phase 1
NCT02305381	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	December 1, 2014	Phase 3
NCT04916470	Novo Nordisk A+S	Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2	June 15, 2021	Phase 3
NCT05071898	University of Maryland, Baltimore	Obesity\|Diabetes Type 2	April 11, 2022	Phase 1
NCT03457012	Novo Nordisk A+S	Diabetes Mellitus, Type 2	March 29, 2018
NCT05035082	Novo Nordisk A+S	Diabetes Mellitus, Type 2	September 1, 2021	Phase 4
NCT05016882	Novo Nordisk A+S	Non-alcoholic Steatohepatitis	August 31, 2021	Phase 2
NCT00813020	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	January 2009	Phase 1
NCT02243098	Novo Nordisk A+S	Diabetes\|Healthy	September 16, 2014	Phase 1
NCT03929679	Novo Nordisk A+S	Diabetes Mellitus, Type 2	May 28, 2019
NCT02128932	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	August 4, 2014	Phase 3
NCT05067621	Yale University\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Type 2 Diabetes Mellitus\|Impaired Glucose Tolerance\|Non-Alcoholic Fatty Liver Disease\|Obesity, Childhood	January 2023	Phase 3
NCT05579249	Novo Nordisk A+S	Obesity	January 20, 2023	Phase 4
NCT05144984	Novo Nordisk A+S	Diabetes Mellitus, Type 2	November 29, 2021	Phase 2
NCT04779697	Yale University\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Obesity	February 1, 2021	Phase 1
NCT02863419	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	August 10, 2016	Phase 3
NCT04969939	Novo Nordisk A+S	Obesity	July 15, 2021	Phase 2
NCT04707469	Novo Nordisk A+S	Diabetes Mellitus, Type 2	January 15, 2021	Phase 3
NCT05046873	Novo Nordisk A+S	Diabetes Mellitus, Type 2	September 6, 2021	Phase 1
NCT05333003	Centre for Addiction and Mental Health	Schizophrenia Spectrum Disorders	May 25, 2022	Not Applicable
NCT03914326	Novo Nordisk A+S	Diabetes Mellitus, Type 2	June 17, 2019	Phase 3
NCT05209165	San Francisco Veterans Affairs Medical Center	Atrial Fibrillation\|Obesity\|Overweight	May 2023	Phase 4
NCT05569772	Universitaire Ziekenhuizen KU Leuven\|UZA\|Universitair Ziekenhuis Brussel\|General Hospital Groeninge\|Onze Lieve Vrouw Hospital\|AZ Delta\|Jessa Hospital\|Ziekenhuis Netwerk Antwerpen (ZNA)\|Vitaz\|Centre Hospitalier Universitaire de Liege\|Erasme University Hospital\|Centre Hospitalier Mouscron	Glucose Intolerance After a Recent History of Gestational Diabetes	March 2023	Phase 3
NCT03357380	Novo Nordisk A+S	Hepatobiliary Disorders\|Non-alcoholic Fatty Liver Disease	November 28, 2017	Phase 1
NCT05444153	Novo Nordisk A+S	Diabetes Mellitus, Type 2	October 6, 2022	Phase 3
NCT05564117	Novo Nordisk A+S	Overweight\|Obesity	October 11, 2022	Phase 3
NCT02877355	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	August 22, 2016	Phase 1
NCT03548935	Novo Nordisk A+S	Metabolism and Nutrition Disorder\|Overweight or Obesity	June 4, 2018	Phase 3
NCT05119179	The University of Texas Health Science Center, Houston\|Vanderbilt University Medical Center	PreDiabetes	November 22, 2021	Phase 4
NCT02147431	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	May 21, 2014	Phase 1
NCT04639414	The Deutsche Diabetes Forschungsgesellschaft e.V.\|Boehringer Ingelheim\|German Center for Diabetes Research\|Federal Ministry of Health, Germany\|Ministry of Innovation, Science and Research in North Rhine-Westphalia\|Novo Nordisk A+S\|German Diabetes Center	Type 2 Diabetes\|Non-alcoholic Steatohepatitis (NASH)\|Non-alcoholic Fatty Liver Disease (NAFLD)	March 26, 2021	Phase 4
NCT01324505	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	March 2011	Phase 1
NCT03987919	Eli Lilly and Company	Type 2 Diabetes	July 30, 2019	Phase 3
NCT04259801	Novo Nordisk A+S	Healthy Volunteers\|Overweight\|Obesity\|Diabetes Mellitus, Type 2	February 17, 2020	Phase 1
NCT03596450	Novo Nordisk A+S	Diabetes Mellitus, Type 2	July 13, 2018	Phase 4
NCT05533632	Novo Nordisk A+S	Diabetes Mellitus, Type 2	April 25, 2022	Phase 4
NCT03985384	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	Type 2 Diabetes\|Coronary Artery Disease	April 30, 2019	Phase 4
NCT00851773	Novo Nordisk A+S	Diabetes\|Healthy	February 2009	Phase 1
NCT05232708	Novo Nordisk A+S	Healthy Volunteers (Diabetes Mellitus, Type 2)	January 19, 2022	Phase 1
NCT03876015	Novo Nordisk A+S	Diabetes Mellitus, Type 2	May 1, 2019
NCT05498610	Novo Nordisk A+S	Diabetes Mellitus, Type 2	August 11, 2022	Phase 1
NCT02014259	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2\|Healthy	December 11, 2013	Phase 1
NCT05236517	Novo Nordisk A+S	Obesity	February 8, 2022	Phase 1
NCT04777409	Novo Nordisk A+S	Early Alzheimer´s Disease	May 18, 2021	Phase 3
NCT02172313	Novo Nordisk A+S	Diabetes\|Healthy	June 2014	Phase 1
NCT05443568	Novo Nordisk A+S	Diabetes Mellitus, Type 2	December 1, 2022
NCT04998136	Novo Nordisk A+S	Obesity	August 15, 2022	Phase 3
NCT00696657	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	June 3, 2008	Phase 2
NCT03989232	Novo Nordisk A+S	Diabetes Mellitus, Type 2	June 19, 2019	Phase 3
NCT04228354	Novo Nordisk A+S	Healthy Volunteers\|Overweight\|Obesity	January 29, 2020	Phase 1
NCT04515849	AstraZeneca	Type 2 Diabetes Mellitus\|Chronic Kidney Diseases	August 31, 2020	Phase 2
NCT04187300	Novo Nordisk A+S	Overweight\|Obesity	December 16, 2019	Phase 1
NCT05254314	Vanderbilt University Medical Center\|National Institute of Allergy and Infectious Diseases (NIAID)	Asthma	September 7, 2022	Phase 2
NCT01619345	Novo Nordisk A+S	Diabetes\|Healthy	June 2012	Phase 1
NCT04007107	Novo Nordisk A+S	Healthy Volunteers Diabetes Mellitus, Type 2\|Healthy Volunteers Overweight\|Healthy Volunteers Obesity	June 27, 2019	Phase 2
NCT04878406	Novo Nordisk A+S	Healthy Volunteers Type 2 Diabetes	May 18, 2021	Phase 1
NCT04524832	Novo Nordisk A+S	Diabetes Mellitus, Type 2	September 29, 2020	Phase 1
NCT03789578	Novo Nordisk A+S	Diabetes Mellitus, Type 2	January 17, 2019	Phase 1
NCT05606471	University of Nottingham\|Medical Research Council	Type 2 Diabetes Mellitus in Obese	September 15, 2021	Phase 4
NCT03689374	Novo Nordisk A+S	Diabetes Mellitus, Type 2	October 1, 2018	Phase 3
NCT04979130	University of Colorado, Denver\|Novo Nordisk A+S	Type 2 Diabetes\|Chronic Inflammation\|Intestinal Permeability	January 1, 2022	Phase 4
NCT05443191	Novo Nordisk A+S	Diabetes Mellitus, Type 2	October 31, 2022
NCT04174755	University College Dublin\|University of Copenhagen\|Rush University Medical Center	Obesity\|HIV-1-infection	June 22, 2022	Not Applicable
NCT05259033	Novo Nordisk A+S	Diabetes Mellitus, Type 2	April 11, 2022	Phase 3
NCT05486065	Novo Nordisk A+S	Diabetes Mellitus, Type 2	August 8, 2022	Phase 2
NCT04094415	Novo Nordisk A+S	Diabetes Mellitus, Type 2	October 28, 2019
NCT05073835	University College, London	Obesity\|Diabetes\|Metabolic Syndrome	November 1, 2022	Phase 3
NCT03884075	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Non-Alcoholic Steatohepatitis\|Non-Alcoholic Fatty Liver Disease	July 24, 2019	Phase 2
NCT02863328	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	August 10, 2016	Phase 3
NCT03659682	Oslo University Hospital	Parkinson Disease	January 2, 2019	Phase 2
NCT03811561	Novo Nordisk A+S	Diabetes Mellitus, Type 2	May 8, 2019	Phase 3
NCT05173714	Srinvasan Beddhu\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|Stanford University\|University of Utah	Chronic Kidney Diseases\|Obesity	December 1, 2021	Phase 2
NCT04126603	Sabyasachi Sen\|George Washington University	Diabetes Mellitus, Type 2	August 1, 2019	Phase 3
NCT04109547	Novo Nordisk A+S	Diabetes Mellitus, Type 2	October 1, 2019	Phase 3
NCT05129891	Novo Nordisk A+S	Healthy Volunteers\|High Blood Cholesterol Levels\|Type 2 Diabetes	November 3, 2021	Phase 1
NCT02453711	Novo Nordisk A+S	Metabolism and Nutrition Disorder\|Obesity	October 1, 2015	Phase 2
NCT02064348	Novo Nordisk A+S	Diabetes\|Healthy	February 26, 2014	Phase 1
NCT04102189	Novo Nordisk A+S	Overweight\|Obesity	October 7, 2019	Phase 3
NCT04982575	Novo Nordisk A+S	Diabetes Mellitus, Type 2	August 2, 2021	Phase 2
NCT03574584	Novo Nordisk A+S	Metabolism and Nutrition Disorders\|Overweight or Obesity	June 18, 2018	Phase 1
NCT04862923	Novo Nordisk A+S	Diabetes Mellitus, Type 2	April 26, 2021
NCT05340868	Medical University of Bialystok	PreDiabetes\|Prediabetic State\|Obesity	September 1, 2022	Not Applicable
NCT04559815	Novo Nordisk A+S	Diabetes Mellitus, Type 2	October 21, 2020
NCT04865770	Novo Nordisk A+S	Diabetes Mellitus, Type 2\|Chronic Kidney Disease	April 28, 2021	Phase 3
NCT04873050	Woman´s\|Novo Nordisk A+S	Pre Diabetes\|Postpartum Disorder	January 13, 2022	Phase 4
NCT03015220	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	January 10, 2017	Phase 3
NCT03951753	Eli Lilly and Company	Diabetes Mellitus, Type 2	June 28, 2019	Phase 1
NCT03600480	Novo Nordisk A+S	Obesity\|Overweight	July 25, 2018	Phase 1
NCT01720446	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	February 21, 2013	Phase 3
NCT04885634	Axel Brandes\|Herlev and Gentofte Hospital\|Hillerod Hospital, Denmark\|Svendborg Hospital\|Hospital of South West Jutland\|Odense University Hospital	Atrial Fibrillation\|Overweight and Obesity	October 2022	Phase 3
NCT04615871	Vladimír D?avík\|Unity Health Toronto\|Canadian Institutes of Health Research (CIHR)\|University of Toronto\|University Health Network, Toronto	Covid19\|Myocardial Injury	September 10, 2021	Phase 2
NCT05586802	Georgios Papadakis\|University of Lausanne Hospitals	Klinefelter Syndrome	January 1, 2023	Phase 3
NCT02827708	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	September 20, 2016	Phase 3
NCT05249881	Aga Khan University\|Rehman Medical Institute - RMI	Diabetes Mellitus, Type 2\|Weight Change, Body	March 10, 2022	Early Phase 1
NCT02461589	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	September 21, 2015	Phase 2
NCT04944992	Merck Sharp & Dohme LLC	Nonalcoholic Fatty Liver Disease\|Nonalcoholic Steatohepatitis	August 4, 2021	Phase 2
NCT03061214	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	August 28, 2017	Phase 3
NCT05078255	Filip Krag Knop\|University Hospital, Gentofte, Copenhagen	Type 2 Diabetes\|Obesity	January 27, 2022	Not Applicable
NCT05616052	Huashan Hospital	Weight Change, Body	December 1, 2022	Phase 4
NCT05577728	Brigham and Women´s Hospital	Diabetes Mellitus, Type 2	July 1, 2021
NCT04152915	Novo Nordisk A+S	Healthy Volunteers\|Diabetes Mellitus, Type 2	November 25, 2019	Phase 1
NCT02692716	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	January 17, 2017	Phase 3
NCT04074161	Novo Nordisk A+S	Overweight\|Obesity	September 11, 2019	Phase 3
NCT04016974	Novo Nordisk A+S	Healthy Volunteers\|Diabetes Mellitus, Type 2	October 8, 2019	Phase 1
NCT05230589	Novo Nordisk A+S	Diabetes Mellitus, Type 2	April 25, 2022
NCT01766245	Novo Nordisk A+S	Diabetes\|Healthy	December 2012	Phase 1
NCT02906930	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	September 20, 2016	Phase 3
NCT05574439	Signe Torekov\|University of Leeds\|Karolinska Institutet\|Holbaek Sygehus\|Rigshospitalet, Denmark\|University of Copenhagen	Obesity, Adolescent	June 1, 2022	Phase 4

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H ₂ O : 100 mg/mL ( 23.65 mM ; Need ultrasonic)

DMSO : 100 mg/mL ( 23.65 mM ; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.2365 mL	1.1827 mL	2.3654 mL
5 mM	0.0473 mL	0.2365 mL	0.4731 mL
10 mM	0.0237 mL	0.1183 mL	0.2365 mL

* Please refer to the solubility information to select the appropriate solvent.